Seeking Alpha

Immunomedics (IMMU) and UCB (UCBJF.PK) tweak their pact for developing and marketing...

Immunomedics (IMMU) and UCB (UCBJF.PK) tweak their pact for developing and marketing epratuzumab, a drug for lupus, cancer and other diseases. The changes predominately concern marketing rights. UCB also gets a five-year warrant to buy 1M Immunomedics shares at $8 apiece; IMMU currently at $3.37.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)